323 related articles for article (PubMed ID: 35530278)
1. Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates.
Jabbarzadeh Kaboli P; Shabani S; Sharma S; Partovi Nasr M; Yamaguchi H; Hung MC
Am J Cancer Res; 2022; 12(4):1671-1685. PubMed ID: 35530278
[TBL] [Abstract][Full Text] [Related]
2. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
Furlanetto J; Marmé F; Loibl S
Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628
[TBL] [Abstract][Full Text] [Related]
3. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
Dent RA; Cescon DW; Bachelot T; Jung KH; Shao ZM; Saji S; Traina TA; Vukovic P; Mapiye D; Maxwell MJ; Schmid P; Cortés J
Future Oncol; 2023 Nov; 19(35):2349-2359. PubMed ID: 37526149
[TBL] [Abstract][Full Text] [Related]
4. Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs).
Dri A; Arpino G; Bianchini G; Curigliano G; Danesi R; De Laurentiis M; Del Mastro L; Fabi A; Generali D; Gennari A; Guarneri V; Santini D; Simoncini E; Zamagni C; Puglisi F
Cancer Treat Rev; 2024 Feb; 123():102672. PubMed ID: 38118302
[TBL] [Abstract][Full Text] [Related]
5. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
Shastry M; Jacob S; Rugo HS; Hamilton E
Breast; 2022 Dec; 66():169-177. PubMed ID: 36302269
[TBL] [Abstract][Full Text] [Related]
6. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy.
Bardia A; Pusztai L; Albain K; Ciruelos EM; Im SA; Hershman D; Kalinsky K; Isaacs C; Loirat D; Testa L; Tokunaga E; Wu J; Dry H; Barlow W; Kozarski R; Maxwell M; Harbeck N; Sharma P
Ther Adv Med Oncol; 2024; 16():17588359241248336. PubMed ID: 38686016
[TBL] [Abstract][Full Text] [Related]
7. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer.
Coates JT; Sun S; Leshchiner I; Thimmiah N; Martin EE; McLoughlin D; Danysh BP; Slowik K; Jacobs RA; Rhrissorrakrai K; Utro F; Levovitz C; Denault E; Walmsley CS; Kambadakone A; Stone JR; Isakoff SJ; Parida L; Juric D; Getz G; Bardia A; Ellisen LW
Cancer Discov; 2021 Oct; 11(10):2436-2445. PubMed ID: 34404686
[TBL] [Abstract][Full Text] [Related]
8. Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial.
Spring LM; Tolaney SM; Fell G; Bossuyt V; Abelman RO; Wu B; Maheswaran S; Trippa L; Comander A; Mulvey T; McLaughlin S; Ryan P; Ryan L; Abraham E; Rosenstock A; Garrido-Castro AC; Lynce F; Moy B; Isakoff SJ; Tung N; Mittendorf EA; Ellisen LW; Bardia A
Ann Oncol; 2024 Mar; 35(3):293-301. PubMed ID: 38092228
[TBL] [Abstract][Full Text] [Related]
9. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
Weiss J; Glode A; Messersmith WA; Diamond J
Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
[No Abstract] [Full Text] [Related]
10. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
O'Shaughnessy J; Brufsky A; Rugo HS; Tolaney SM; Punie K; Sardesai S; Hamilton E; Loirat D; Traina T; Leon-Ferre R; Hurvitz SA; Kalinsky K; Bardia A; Henry S; Mayer I; Zhu Y; Phan S; Cortés J
Breast Cancer Res Treat; 2022 Sep; 195(2):127-139. PubMed ID: 35545724
[TBL] [Abstract][Full Text] [Related]
11. Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus.
Hoppe S; Meder L; Gebauer F; Ullrich RT; Zander T; Hillmer AM; Buettner R; Plum P; Puppe J; Malter W; Quaas A
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230712
[TBL] [Abstract][Full Text] [Related]
12. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.
Schreiber AR; Andress M; Diamond JR
Expert Rev Anticancer Ther; 2021 Dec; 21(12):1303-1311. PubMed ID: 34651524
[No Abstract] [Full Text] [Related]
13. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
Han C; Perrone E; Zeybek B; Bellone S; Tymon-Rosario J; Altwerger G; Menderes G; Feinberg J; Haines K; Muller Karger ME; Bianchi A; Zammataro L; Manzano A; Bonazzoli E; Manara P; Buza N; Hui P; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Lopez S; Santin AD
Gynecol Oncol; 2020 Feb; 156(2):430-438. PubMed ID: 31839338
[TBL] [Abstract][Full Text] [Related]
14. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
Nagayama A; Vidula N; Bardia A
Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696
[TBL] [Abstract][Full Text] [Related]
15. A literature review of the promising future of
Wen Y; Ouyang D; Zou Q; Chen Q; Luo N; He H; Anwar M; Yi W
Ann Transl Med; 2022 Dec; 10(24):1403. PubMed ID: 36660684
[TBL] [Abstract][Full Text] [Related]
16. Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.
Spring LM; Nakajima E; Hutchinson J; Viscosi E; Blouin G; Weekes C; Rugo H; Moy B; Bardia A
Oncologist; 2021 Oct; 26(10):827-834. PubMed ID: 34176192
[TBL] [Abstract][Full Text] [Related]
17. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.
Goldenberg DM; Sharkey RM
MAbs; 2019; 11(6):987-995. PubMed ID: 31208270
[TBL] [Abstract][Full Text] [Related]
18. Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer.
Schipilliti FM; Drittone D; Mazzuca F; La Forgia D; Guven DC; Rizzo A
Heliyon; 2024 Apr; 10(7):e28385. PubMed ID: 38560142
[TBL] [Abstract][Full Text] [Related]
19. TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer.
Cortesi M; Zanoni M; Maltoni R; Ravaioli S; Tumedei MM; Pirini F; Bravaccini S
Expert Opin Ther Targets; 2022 Jul; 26(7):593-602. PubMed ID: 35962580
[TBL] [Abstract][Full Text] [Related]
20. Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?
Zardavas D
Expert Opin Investig Drugs; 2022 Jun; 31(6):633-644. PubMed ID: 35451891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]